nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—Folic Acid Metabolism Inhibitors—Methotrexate—lymphatic system cancer	0.37	1	CiPCiCtD
Pemetrexed—Methotrexate—lymphatic system cancer	0.241	1	CrCtD
Pemetrexed—SLC29A1—Fludarabine—lymphatic system cancer	0.0432	0.217	CbGbCtD
Pemetrexed—DCK—Fludarabine—lymphatic system cancer	0.04	0.201	CbGbCtD
Pemetrexed—Tetrahydrofolic acid—Methotrexate—lymphatic system cancer	0.0319	0.2	CrCrCtD
Pemetrexed—Folic Acid—Methotrexate—lymphatic system cancer	0.0319	0.2	CrCrCtD
Pemetrexed—Leucovorin—Methotrexate—lymphatic system cancer	0.0319	0.2	CrCrCtD
Pemetrexed—Pralatrexate—Methotrexate—lymphatic system cancer	0.0319	0.2	CrCrCtD
Pemetrexed—Raltitrexed—Methotrexate—lymphatic system cancer	0.0319	0.2	CrCrCtD
Pemetrexed—SLC29A1—Cytarabine—lymphatic system cancer	0.0295	0.148	CbGbCtD
Pemetrexed—DCK—Cytarabine—lymphatic system cancer	0.0273	0.137	CbGbCtD
Pemetrexed—ATIC—Methotrexate—lymphatic system cancer	0.0222	0.111	CbGbCtD
Pemetrexed—SLC46A1—Methotrexate—lymphatic system cancer	0.0176	0.0885	CbGbCtD
Pemetrexed—DHFR—Methotrexate—lymphatic system cancer	0.0113	0.0566	CbGbCtD
Pemetrexed—TYMS—Methotrexate—lymphatic system cancer	0.00784	0.0394	CbGbCtD
Pemetrexed—TYMS—Podofilox—Teniposide—lymphatic system cancer	0.000267	0.4	CbGdCrCtD
Pemetrexed—TYMS—Vinorelbine—Vincristine—lymphatic system cancer	0.000159	0.238	CbGdCrCtD
Pemetrexed—TYMS—Vinblastine—Vincristine—lymphatic system cancer	0.000109	0.164	CbGdCrCtD
Pemetrexed—Pruritus—Mechlorethamine—lymphatic system cancer	7.21e-05	0.00246	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	7.2e-05	0.00246	CcSEcCtD
Pemetrexed—Anorexia—Teniposide—lymphatic system cancer	7.17e-05	0.00244	CcSEcCtD
Pemetrexed—Pancytopenia—Carmustine—lymphatic system cancer	7.06e-05	0.00241	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	7.05e-05	0.0024	CcSEcCtD
Pemetrexed—Diarrhoea—Mechlorethamine—lymphatic system cancer	6.98e-05	0.00238	CcSEcCtD
Pemetrexed—Neutropenia—Carmustine—lymphatic system cancer	6.95e-05	0.00237	CcSEcCtD
Pemetrexed—Arthralgia—Fludarabine—lymphatic system cancer	6.89e-05	0.00235	CcSEcCtD
Pemetrexed—Myalgia—Fludarabine—lymphatic system cancer	6.89e-05	0.00235	CcSEcCtD
Pemetrexed—TYMS—Azacitidine—Fludarabine—lymphatic system cancer	6.77e-05	0.102	CbGdCrCtD
Pemetrexed—Pancytopenia—Vincristine—lymphatic system cancer	6.74e-05	0.0023	CcSEcCtD
Pemetrexed—Dyspnoea—Teniposide—lymphatic system cancer	6.7e-05	0.00228	CcSEcCtD
Pemetrexed—Neutropenia—Vincristine—lymphatic system cancer	6.64e-05	0.00226	CcSEcCtD
Pemetrexed—Anaphylactic shock—Fludarabine—lymphatic system cancer	6.61e-05	0.00225	CcSEcCtD
Pemetrexed—Oedema—Fludarabine—lymphatic system cancer	6.61e-05	0.00225	CcSEcCtD
Pemetrexed—Pancytopenia—Mitoxantrone—lymphatic system cancer	6.56e-05	0.00224	CcSEcCtD
Pemetrexed—Infection—Fludarabine—lymphatic system cancer	6.56e-05	0.00224	CcSEcCtD
Pemetrexed—Decreased appetite—Teniposide—lymphatic system cancer	6.53e-05	0.00223	CcSEcCtD
Pemetrexed—Renal failure—Carmustine—lymphatic system cancer	6.52e-05	0.00222	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Carmustine—lymphatic system cancer	6.5e-05	0.00222	CcSEcCtD
Pemetrexed—Vomiting—Mechlorethamine—lymphatic system cancer	6.48e-05	0.00221	CcSEcCtD
Pemetrexed—Nervous system disorder—Fludarabine—lymphatic system cancer	6.48e-05	0.00221	CcSEcCtD
Pemetrexed—Thrombocytopenia—Fludarabine—lymphatic system cancer	6.47e-05	0.00221	CcSEcCtD
Pemetrexed—Neutropenia—Mitoxantrone—lymphatic system cancer	6.46e-05	0.0022	CcSEcCtD
Pemetrexed—Stomatitis—Carmustine—lymphatic system cancer	6.46e-05	0.0022	CcSEcCtD
Pemetrexed—Rash—Mechlorethamine—lymphatic system cancer	6.43e-05	0.00219	CcSEcCtD
Pemetrexed—Dermatitis—Mechlorethamine—lymphatic system cancer	6.42e-05	0.00219	CcSEcCtD
Pemetrexed—TYMS—Azacitidine—Cytarabine—lymphatic system cancer	6.39e-05	0.096	CbGdCrCtD
Pemetrexed—Anorexia—Fludarabine—lymphatic system cancer	6.3e-05	0.00215	CcSEcCtD
Pemetrexed—Acute coronary syndrome—Vincristine—lymphatic system cancer	6.24e-05	0.00213	CcSEcCtD
Pemetrexed—Myocardial infarction—Vincristine—lymphatic system cancer	6.2e-05	0.00211	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Vincristine—lymphatic system cancer	6.2e-05	0.00211	CcSEcCtD
Pemetrexed—Stomatitis—Vincristine—lymphatic system cancer	6.17e-05	0.0021	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Teniposide—lymphatic system cancer	6.15e-05	0.0021	CcSEcCtD
Pemetrexed—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	6.08e-05	0.00207	CcSEcCtD
Pemetrexed—Renal failure—Mitoxantrone—lymphatic system cancer	6.06e-05	0.00207	CcSEcCtD
Pemetrexed—Nausea—Mechlorethamine—lymphatic system cancer	6.06e-05	0.00206	CcSEcCtD
Pemetrexed—Myocardial infarction—Mitoxantrone—lymphatic system cancer	6.04e-05	0.00206	CcSEcCtD
Pemetrexed—Alopecia—Bleomycin—lymphatic system cancer	6.03e-05	0.00205	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	6.02e-05	0.00205	CcSEcCtD
Pemetrexed—Stomatitis—Mitoxantrone—lymphatic system cancer	6.01e-05	0.00205	CcSEcCtD
Pemetrexed—Conjunctivitis—Mitoxantrone—lymphatic system cancer	5.99e-05	0.00204	CcSEcCtD
Pemetrexed—Urticaria—Teniposide—lymphatic system cancer	5.97e-05	0.00204	CcSEcCtD
Pemetrexed—Abdominal pain—Teniposide—lymphatic system cancer	5.94e-05	0.00203	CcSEcCtD
Pemetrexed—Body temperature increased—Teniposide—lymphatic system cancer	5.94e-05	0.00203	CcSEcCtD
Pemetrexed—Erythema—Bleomycin—lymphatic system cancer	5.94e-05	0.00202	CcSEcCtD
Pemetrexed—Dyspnoea—Fludarabine—lymphatic system cancer	5.89e-05	0.00201	CcSEcCtD
Pemetrexed—Dyspepsia—Fludarabine—lymphatic system cancer	5.82e-05	0.00198	CcSEcCtD
Pemetrexed—Agranulocytosis—Mitoxantrone—lymphatic system cancer	5.75e-05	0.00196	CcSEcCtD
Pemetrexed—Decreased appetite—Fludarabine—lymphatic system cancer	5.74e-05	0.00196	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	5.7e-05	0.00194	CcSEcCtD
Pemetrexed—Fatigue—Fludarabine—lymphatic system cancer	5.7e-05	0.00194	CcSEcCtD
Pemetrexed—Pain—Fludarabine—lymphatic system cancer	5.65e-05	0.00193	CcSEcCtD
Pemetrexed—Constipation—Fludarabine—lymphatic system cancer	5.65e-05	0.00193	CcSEcCtD
Pemetrexed—Urinary tract disorder—Vincristine—lymphatic system cancer	5.61e-05	0.00191	CcSEcCtD
Pemetrexed—Respiratory failure—Methotrexate—lymphatic system cancer	5.59e-05	0.00191	CcSEcCtD
Pemetrexed—Urethral disorder—Vincristine—lymphatic system cancer	5.57e-05	0.0019	CcSEcCtD
Pemetrexed—Eye disorder—Carmustine—lymphatic system cancer	5.56e-05	0.0019	CcSEcCtD
Pemetrexed—Hypersensitivity—Teniposide—lymphatic system cancer	5.54e-05	0.00189	CcSEcCtD
Pemetrexed—Hepatitis—Mitoxantrone—lymphatic system cancer	5.53e-05	0.00189	CcSEcCtD
Pemetrexed—Pharyngitis—Mitoxantrone—lymphatic system cancer	5.49e-05	0.00187	CcSEcCtD
Pemetrexed—Pulmonary embolism—Methotrexate—lymphatic system cancer	5.49e-05	0.00187	CcSEcCtD
Pemetrexed—Anaemia—Bleomycin—lymphatic system cancer	5.49e-05	0.00187	CcSEcCtD
Pemetrexed—Asthenia—Teniposide—lymphatic system cancer	5.39e-05	0.00184	CcSEcCtD
Pemetrexed—Pruritus—Teniposide—lymphatic system cancer	5.32e-05	0.00181	CcSEcCtD
Pemetrexed—Arrhythmia—Carmustine—lymphatic system cancer	5.32e-05	0.00181	CcSEcCtD
Pemetrexed—Leukopenia—Bleomycin—lymphatic system cancer	5.31e-05	0.00181	CcSEcCtD
Pemetrexed—Alopecia—Carmustine—lymphatic system cancer	5.26e-05	0.00179	CcSEcCtD
Pemetrexed—Skin exfoliation—Methotrexate—lymphatic system cancer	5.24e-05	0.00179	CcSEcCtD
Pemetrexed—Body temperature increased—Fludarabine—lymphatic system cancer	5.22e-05	0.00178	CcSEcCtD
Pemetrexed—Malnutrition—Carmustine—lymphatic system cancer	5.18e-05	0.00177	CcSEcCtD
Pemetrexed—Erythema—Carmustine—lymphatic system cancer	5.18e-05	0.00177	CcSEcCtD
Pemetrexed—Diarrhoea—Teniposide—lymphatic system cancer	5.14e-05	0.00175	CcSEcCtD
Pemetrexed—Chest pain—Bleomycin—lymphatic system cancer	5.05e-05	0.00172	CcSEcCtD
Pemetrexed—Myalgia—Bleomycin—lymphatic system cancer	5.05e-05	0.00172	CcSEcCtD
Pemetrexed—Alopecia—Vincristine—lymphatic system cancer	5.02e-05	0.00171	CcSEcCtD
Pemetrexed—Arrhythmia—Mitoxantrone—lymphatic system cancer	4.94e-05	0.00169	CcSEcCtD
Pemetrexed—Alopecia—Mitoxantrone—lymphatic system cancer	4.89e-05	0.00167	CcSEcCtD
Pemetrexed—Hypersensitivity—Fludarabine—lymphatic system cancer	4.87e-05	0.00166	CcSEcCtD
Pemetrexed—Oedema—Bleomycin—lymphatic system cancer	4.84e-05	0.00165	CcSEcCtD
Pemetrexed—Anaphylactic shock—Bleomycin—lymphatic system cancer	4.84e-05	0.00165	CcSEcCtD
Pemetrexed—Erythema—Mitoxantrone—lymphatic system cancer	4.82e-05	0.00164	CcSEcCtD
Pemetrexed—Infection—Bleomycin—lymphatic system cancer	4.81e-05	0.00164	CcSEcCtD
Pemetrexed—Anaemia—Carmustine—lymphatic system cancer	4.79e-05	0.00163	CcSEcCtD
Pemetrexed—Vomiting—Teniposide—lymphatic system cancer	4.78e-05	0.00163	CcSEcCtD
Pemetrexed—Sepsis—Methotrexate—lymphatic system cancer	4.76e-05	0.00162	CcSEcCtD
Pemetrexed—Thrombocytopenia—Bleomycin—lymphatic system cancer	4.74e-05	0.00162	CcSEcCtD
Pemetrexed—Asthenia—Fludarabine—lymphatic system cancer	4.74e-05	0.00162	CcSEcCtD
Pemetrexed—Rash—Teniposide—lymphatic system cancer	4.74e-05	0.00162	CcSEcCtD
Pemetrexed—Dermatitis—Teniposide—lymphatic system cancer	4.74e-05	0.00161	CcSEcCtD
Pemetrexed—Dysgeusia—Mitoxantrone—lymphatic system cancer	4.72e-05	0.00161	CcSEcCtD
Pemetrexed—Pruritus—Fludarabine—lymphatic system cancer	4.67e-05	0.00159	CcSEcCtD
Pemetrexed—Leukopenia—Carmustine—lymphatic system cancer	4.64e-05	0.00158	CcSEcCtD
Pemetrexed—Anorexia—Bleomycin—lymphatic system cancer	4.62e-05	0.00157	CcSEcCtD
Pemetrexed—Anaemia—Vincristine—lymphatic system cancer	4.57e-05	0.00156	CcSEcCtD
Pemetrexed—Diarrhoea—Fludarabine—lymphatic system cancer	4.52e-05	0.00154	CcSEcCtD
Pemetrexed—Hypertension—Carmustine—lymphatic system cancer	4.47e-05	0.00152	CcSEcCtD
Pemetrexed—Nausea—Teniposide—lymphatic system cancer	4.47e-05	0.00152	CcSEcCtD
Pemetrexed—Anaemia—Mitoxantrone—lymphatic system cancer	4.45e-05	0.00152	CcSEcCtD
Pemetrexed—Leukopenia—Vincristine—lymphatic system cancer	4.43e-05	0.00151	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	4.41e-05	0.0015	CcSEcCtD
Pemetrexed—Chest pain—Carmustine—lymphatic system cancer	4.41e-05	0.0015	CcSEcCtD
Pemetrexed—Myalgia—Carmustine—lymphatic system cancer	4.41e-05	0.0015	CcSEcCtD
Pemetrexed—Dyspnoea—Bleomycin—lymphatic system cancer	4.32e-05	0.00147	CcSEcCtD
Pemetrexed—Renal failure acute—Methotrexate—lymphatic system cancer	4.32e-05	0.00147	CcSEcCtD
Pemetrexed—Leukopenia—Mitoxantrone—lymphatic system cancer	4.31e-05	0.00147	CcSEcCtD
Pemetrexed—Hypertension—Vincristine—lymphatic system cancer	4.27e-05	0.00146	CcSEcCtD
Pemetrexed—Oedema—Carmustine—lymphatic system cancer	4.23e-05	0.00144	CcSEcCtD
Pemetrexed—Decreased appetite—Bleomycin—lymphatic system cancer	4.21e-05	0.00144	CcSEcCtD
Pemetrexed—Myalgia—Vincristine—lymphatic system cancer	4.21e-05	0.00144	CcSEcCtD
Pemetrexed—Infection—Carmustine—lymphatic system cancer	4.2e-05	0.00143	CcSEcCtD
Pemetrexed—Vomiting—Fludarabine—lymphatic system cancer	4.2e-05	0.00143	CcSEcCtD
Pemetrexed—Rash—Fludarabine—lymphatic system cancer	4.17e-05	0.00142	CcSEcCtD
Pemetrexed—Dermatitis—Fludarabine—lymphatic system cancer	4.16e-05	0.00142	CcSEcCtD
Pemetrexed—Hypertension—Mitoxantrone—lymphatic system cancer	4.16e-05	0.00142	CcSEcCtD
Pemetrexed—Pain—Bleomycin—lymphatic system cancer	4.14e-05	0.00141	CcSEcCtD
Pemetrexed—Thrombocytopenia—Carmustine—lymphatic system cancer	4.14e-05	0.00141	CcSEcCtD
Pemetrexed—Chest pain—Mitoxantrone—lymphatic system cancer	4.1e-05	0.0014	CcSEcCtD
Pemetrexed—Arthralgia—Mitoxantrone—lymphatic system cancer	4.1e-05	0.0014	CcSEcCtD
Pemetrexed—Myalgia—Mitoxantrone—lymphatic system cancer	4.1e-05	0.0014	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Methotrexate—lymphatic system cancer	4.07e-05	0.00139	CcSEcCtD
Pemetrexed—Anaphylactic shock—Vincristine—lymphatic system cancer	4.04e-05	0.00138	CcSEcCtD
Pemetrexed—Oedema—Vincristine—lymphatic system cancer	4.04e-05	0.00138	CcSEcCtD
Pemetrexed—Anorexia—Carmustine—lymphatic system cancer	4.03e-05	0.00137	CcSEcCtD
Pemetrexed—Infection—Vincristine—lymphatic system cancer	4.01e-05	0.00137	CcSEcCtD
Pemetrexed—Nervous system disorder—Vincristine—lymphatic system cancer	3.96e-05	0.00135	CcSEcCtD
Pemetrexed—Thrombocytopenia—Vincristine—lymphatic system cancer	3.95e-05	0.00135	CcSEcCtD
Pemetrexed—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	3.93e-05	0.00134	CcSEcCtD
Pemetrexed—Oedema—Mitoxantrone—lymphatic system cancer	3.93e-05	0.00134	CcSEcCtD
Pemetrexed—Nausea—Fludarabine—lymphatic system cancer	3.92e-05	0.00134	CcSEcCtD
Pemetrexed—Infection—Mitoxantrone—lymphatic system cancer	3.91e-05	0.00133	CcSEcCtD
Pemetrexed—Shock—Mitoxantrone—lymphatic system cancer	3.87e-05	0.00132	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	3.85e-05	0.00131	CcSEcCtD
Pemetrexed—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	3.85e-05	0.00131	CcSEcCtD
Pemetrexed—Urticaria—Bleomycin—lymphatic system cancer	3.85e-05	0.00131	CcSEcCtD
Pemetrexed—Anorexia—Vincristine—lymphatic system cancer	3.85e-05	0.00131	CcSEcCtD
Pemetrexed—Body temperature increased—Bleomycin—lymphatic system cancer	3.83e-05	0.00131	CcSEcCtD
Pemetrexed—Skin disorder—Mitoxantrone—lymphatic system cancer	3.82e-05	0.0013	CcSEcCtD
Pemetrexed—Mood swings—Methotrexate—lymphatic system cancer	3.77e-05	0.00129	CcSEcCtD
Pemetrexed—Dyspnoea—Carmustine—lymphatic system cancer	3.77e-05	0.00129	CcSEcCtD
Pemetrexed—Anorexia—Mitoxantrone—lymphatic system cancer	3.75e-05	0.00128	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	3.68e-05	0.00125	CcSEcCtD
Pemetrexed—Decreased appetite—Carmustine—lymphatic system cancer	3.68e-05	0.00125	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Carmustine—lymphatic system cancer	3.65e-05	0.00124	CcSEcCtD
Pemetrexed—Pain—Carmustine—lymphatic system cancer	3.62e-05	0.00123	CcSEcCtD
Pemetrexed—Constipation—Carmustine—lymphatic system cancer	3.62e-05	0.00123	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	3.59e-05	0.00122	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	3.58e-05	0.00122	CcSEcCtD
Pemetrexed—Hypersensitivity—Bleomycin—lymphatic system cancer	3.57e-05	0.00122	CcSEcCtD
Pemetrexed—Decreased appetite—Vincristine—lymphatic system cancer	3.51e-05	0.0012	CcSEcCtD
Pemetrexed—Dyspnoea—Mitoxantrone—lymphatic system cancer	3.5e-05	0.00119	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Vincristine—lymphatic system cancer	3.48e-05	0.00119	CcSEcCtD
Pemetrexed—Fatigue—Vincristine—lymphatic system cancer	3.48e-05	0.00119	CcSEcCtD
Pemetrexed—Asthenia—Bleomycin—lymphatic system cancer	3.48e-05	0.00118	CcSEcCtD
Pemetrexed—Dyspepsia—Mitoxantrone—lymphatic system cancer	3.46e-05	0.00118	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Carmustine—lymphatic system cancer	3.46e-05	0.00118	CcSEcCtD
Pemetrexed—Pain—Vincristine—lymphatic system cancer	3.45e-05	0.00118	CcSEcCtD
Pemetrexed—Constipation—Vincristine—lymphatic system cancer	3.45e-05	0.00118	CcSEcCtD
Pemetrexed—Pruritus—Bleomycin—lymphatic system cancer	3.43e-05	0.00117	CcSEcCtD
Pemetrexed—Decreased appetite—Mitoxantrone—lymphatic system cancer	3.42e-05	0.00116	CcSEcCtD
Pemetrexed—Fatigue—Mitoxantrone—lymphatic system cancer	3.39e-05	0.00116	CcSEcCtD
Pemetrexed—Pancreatitis—Methotrexate—lymphatic system cancer	3.38e-05	0.00115	CcSEcCtD
Pemetrexed—Constipation—Mitoxantrone—lymphatic system cancer	3.36e-05	0.00115	CcSEcCtD
Pemetrexed—Pain—Mitoxantrone—lymphatic system cancer	3.36e-05	0.00115	CcSEcCtD
Pemetrexed—Body temperature increased—Carmustine—lymphatic system cancer	3.34e-05	0.00114	CcSEcCtD
Pemetrexed—Abdominal pain—Carmustine—lymphatic system cancer	3.34e-05	0.00114	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Vincristine—lymphatic system cancer	3.3e-05	0.00113	CcSEcCtD
Pemetrexed—Pancytopenia—Methotrexate—lymphatic system cancer	3.27e-05	0.00112	CcSEcCtD
Pemetrexed—Neutropenia—Methotrexate—lymphatic system cancer	3.22e-05	0.0011	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	3.21e-05	0.0011	CcSEcCtD
Pemetrexed—Abdominal pain—Vincristine—lymphatic system cancer	3.19e-05	0.00109	CcSEcCtD
Pemetrexed—Body temperature increased—Vincristine—lymphatic system cancer	3.19e-05	0.00109	CcSEcCtD
Pemetrexed—Urticaria—Mitoxantrone—lymphatic system cancer	3.12e-05	0.00106	CcSEcCtD
Pemetrexed—Hypersensitivity—Carmustine—lymphatic system cancer	3.12e-05	0.00106	CcSEcCtD
Pemetrexed—Body temperature increased—Mitoxantrone—lymphatic system cancer	3.11e-05	0.00106	CcSEcCtD
Pemetrexed—Abdominal pain—Mitoxantrone—lymphatic system cancer	3.11e-05	0.00106	CcSEcCtD
Pemetrexed—Vomiting—Bleomycin—lymphatic system cancer	3.08e-05	0.00105	CcSEcCtD
Pemetrexed—Infestation NOS—Methotrexate—lymphatic system cancer	3.07e-05	0.00105	CcSEcCtD
Pemetrexed—Infestation—Methotrexate—lymphatic system cancer	3.07e-05	0.00105	CcSEcCtD
Pemetrexed—Rash—Bleomycin—lymphatic system cancer	3.05e-05	0.00104	CcSEcCtD
Pemetrexed—Dermatitis—Bleomycin—lymphatic system cancer	3.05e-05	0.00104	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	3.04e-05	0.00104	CcSEcCtD
Pemetrexed—Asthenia—Carmustine—lymphatic system cancer	3.03e-05	0.00103	CcSEcCtD
Pemetrexed—Renal failure—Methotrexate—lymphatic system cancer	3.02e-05	0.00103	CcSEcCtD
Pemetrexed—Stomatitis—Methotrexate—lymphatic system cancer	2.99e-05	0.00102	CcSEcCtD
Pemetrexed—Conjunctivitis—Methotrexate—lymphatic system cancer	2.98e-05	0.00102	CcSEcCtD
Pemetrexed—Hypersensitivity—Vincristine—lymphatic system cancer	2.97e-05	0.00101	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Methotrexate—lymphatic system cancer	2.9e-05	0.00099	CcSEcCtD
Pemetrexed—Hypersensitivity—Mitoxantrone—lymphatic system cancer	2.9e-05	0.000987	CcSEcCtD
Pemetrexed—Asthenia—Vincristine—lymphatic system cancer	2.9e-05	0.000987	CcSEcCtD
Pemetrexed—Diarrhoea—Carmustine—lymphatic system cancer	2.89e-05	0.000986	CcSEcCtD
Pemetrexed—Nausea—Bleomycin—lymphatic system cancer	2.88e-05	0.000981	CcSEcCtD
Pemetrexed—Agranulocytosis—Methotrexate—lymphatic system cancer	2.87e-05	0.000977	CcSEcCtD
Pemetrexed—Asthenia—Mitoxantrone—lymphatic system cancer	2.82e-05	0.000962	CcSEcCtD
Pemetrexed—Dizziness—Carmustine—lymphatic system cancer	2.8e-05	0.000953	CcSEcCtD
Pemetrexed—Diarrhoea—Vincristine—lymphatic system cancer	2.76e-05	0.000942	CcSEcCtD
Pemetrexed—Hepatitis—Methotrexate—lymphatic system cancer	2.76e-05	0.00094	CcSEcCtD
Pemetrexed—Pharyngitis—Methotrexate—lymphatic system cancer	2.74e-05	0.000933	CcSEcCtD
Pemetrexed—Urinary tract disorder—Methotrexate—lymphatic system cancer	2.72e-05	0.000928	CcSEcCtD
Pemetrexed—Urethral disorder—Methotrexate—lymphatic system cancer	2.7e-05	0.000921	CcSEcCtD
Pemetrexed—Diarrhoea—Mitoxantrone—lymphatic system cancer	2.69e-05	0.000917	CcSEcCtD
Pemetrexed—Vomiting—Carmustine—lymphatic system cancer	2.69e-05	0.000917	CcSEcCtD
Pemetrexed—Dizziness—Vincristine—lymphatic system cancer	2.67e-05	0.00091	CcSEcCtD
Pemetrexed—Rash—Carmustine—lymphatic system cancer	2.67e-05	0.000909	CcSEcCtD
Pemetrexed—Dermatitis—Carmustine—lymphatic system cancer	2.66e-05	0.000908	CcSEcCtD
Pemetrexed—Erythema multiforme—Methotrexate—lymphatic system cancer	2.61e-05	0.000889	CcSEcCtD
Pemetrexed—Eye disorder—Methotrexate—lymphatic system cancer	2.58e-05	0.000878	CcSEcCtD
Pemetrexed—Vomiting—Vincristine—lymphatic system cancer	2.57e-05	0.000875	CcSEcCtD
Pemetrexed—Rash—Vincristine—lymphatic system cancer	2.55e-05	0.000868	CcSEcCtD
Pemetrexed—Dermatitis—Vincristine—lymphatic system cancer	2.54e-05	0.000867	CcSEcCtD
Pemetrexed—Nausea—Carmustine—lymphatic system cancer	2.51e-05	0.000856	CcSEcCtD
Pemetrexed—Vomiting—Mitoxantrone—lymphatic system cancer	2.5e-05	0.000852	CcSEcCtD
Pemetrexed—Rash—Mitoxantrone—lymphatic system cancer	2.48e-05	0.000845	CcSEcCtD
Pemetrexed—Dermatitis—Mitoxantrone—lymphatic system cancer	2.48e-05	0.000844	CcSEcCtD
Pemetrexed—Alopecia—Methotrexate—lymphatic system cancer	2.44e-05	0.00083	CcSEcCtD
Pemetrexed—Malnutrition—Methotrexate—lymphatic system cancer	2.4e-05	0.000818	CcSEcCtD
Pemetrexed—Erythema—Methotrexate—lymphatic system cancer	2.4e-05	0.000818	CcSEcCtD
Pemetrexed—Nausea—Vincristine—lymphatic system cancer	2.4e-05	0.000817	CcSEcCtD
Pemetrexed—Dysgeusia—Methotrexate—lymphatic system cancer	2.35e-05	0.000801	CcSEcCtD
Pemetrexed—Nausea—Mitoxantrone—lymphatic system cancer	2.33e-05	0.000796	CcSEcCtD
Pemetrexed—Anaemia—Methotrexate—lymphatic system cancer	2.22e-05	0.000756	CcSEcCtD
Pemetrexed—Leukopenia—Methotrexate—lymphatic system cancer	2.15e-05	0.000732	CcSEcCtD
Pemetrexed—Myalgia—Methotrexate—lymphatic system cancer	2.04e-05	0.000697	CcSEcCtD
Pemetrexed—Chest pain—Methotrexate—lymphatic system cancer	2.04e-05	0.000697	CcSEcCtD
Pemetrexed—Arthralgia—Methotrexate—lymphatic system cancer	2.04e-05	0.000697	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	2.03e-05	0.000692	CcSEcCtD
Pemetrexed—Anaphylactic shock—Methotrexate—lymphatic system cancer	1.96e-05	0.000668	CcSEcCtD
Pemetrexed—Infection—Methotrexate—lymphatic system cancer	1.95e-05	0.000663	CcSEcCtD
Pemetrexed—Nervous system disorder—Methotrexate—lymphatic system cancer	1.92e-05	0.000655	CcSEcCtD
Pemetrexed—Thrombocytopenia—Methotrexate—lymphatic system cancer	1.92e-05	0.000654	CcSEcCtD
Pemetrexed—Skin disorder—Methotrexate—lymphatic system cancer	1.9e-05	0.000649	CcSEcCtD
Pemetrexed—Anorexia—Methotrexate—lymphatic system cancer	1.87e-05	0.000636	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	1.78e-05	0.000608	CcSEcCtD
Pemetrexed—Dyspnoea—Methotrexate—lymphatic system cancer	1.75e-05	0.000595	CcSEcCtD
Pemetrexed—Dyspepsia—Methotrexate—lymphatic system cancer	1.72e-05	0.000588	CcSEcCtD
Pemetrexed—Decreased appetite—Methotrexate—lymphatic system cancer	1.7e-05	0.00058	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	1.69e-05	0.000576	CcSEcCtD
Pemetrexed—Fatigue—Methotrexate—lymphatic system cancer	1.69e-05	0.000576	CcSEcCtD
Pemetrexed—Pain—Methotrexate—lymphatic system cancer	1.67e-05	0.000571	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Methotrexate—lymphatic system cancer	1.6e-05	0.000546	CcSEcCtD
Pemetrexed—Urticaria—Methotrexate—lymphatic system cancer	1.56e-05	0.00053	CcSEcCtD
Pemetrexed—Abdominal pain—Methotrexate—lymphatic system cancer	1.55e-05	0.000528	CcSEcCtD
Pemetrexed—Body temperature increased—Methotrexate—lymphatic system cancer	1.55e-05	0.000528	CcSEcCtD
Pemetrexed—Hypersensitivity—Methotrexate—lymphatic system cancer	1.44e-05	0.000492	CcSEcCtD
Pemetrexed—Asthenia—Methotrexate—lymphatic system cancer	1.41e-05	0.000479	CcSEcCtD
Pemetrexed—Pruritus—Methotrexate—lymphatic system cancer	1.39e-05	0.000472	CcSEcCtD
Pemetrexed—Diarrhoea—Methotrexate—lymphatic system cancer	1.34e-05	0.000457	CcSEcCtD
Pemetrexed—Dizziness—Methotrexate—lymphatic system cancer	1.3e-05	0.000442	CcSEcCtD
Pemetrexed—Vomiting—Methotrexate—lymphatic system cancer	1.25e-05	0.000425	CcSEcCtD
Pemetrexed—Rash—Methotrexate—lymphatic system cancer	1.23e-05	0.000421	CcSEcCtD
Pemetrexed—Dermatitis—Methotrexate—lymphatic system cancer	1.23e-05	0.000421	CcSEcCtD
Pemetrexed—Nausea—Methotrexate—lymphatic system cancer	1.16e-05	0.000397	CcSEcCtD
